Last update 08 May 2025

Tretinoin

Overview

Basic Info

SummaryVesanoid, also known as Tretinoin, is a vitamin A derivative that has been given the green light for treating acne vulgaris and specific forms of promyelocytic leukemia. This drug, originating from the pharmaceutical company Bausch Health Americas, acts as a RARs agonist that helps regulate gene expression and cell differentiation in a multifaceted manner, displaying a higher level of complexity in its mechanism of action. With its initial approval in the United States in 1971, Tretinoin has been increasingly incorporated into numerous over-the-counter products, due to its demonstrated efficacy in managing a wide range of skin conditions. Because of its reliability in the management of acne vulgaris, Tretinoin has gained widespread popularity among dermatologists and individuals seeking to alleviate this all-too-common skin condition. Its continued use in contemporary medicine reinforces Tretinoin's value as a valuable weapon in the struggle against acne and other cutaneous disorders, lending credence to its ongoing utility.
Drug Type
Small molecule drug
Synonyms
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid, 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL), ATRA
+ [40]
Target
Action
agonists
Mechanism
RARs agonists(Retinoic acid receptors agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (20 Oct 1971),
RegulationOrphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H28O2
InChIKeySHGAZHPCJJPHSC-YCNIQYBTSA-N
CAS Registry302-79-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Facial wrinkles
United States
31 Aug 2000
Acute Promyelocytic Leukemia
Spain
05 Aug 1996
Acute Promyelocytic Leukemia
Netherlands
05 Aug 1996
Acute Promyelocytic Leukemia
Portugal
05 Aug 1996
Acute Promyelocytic Leukemia
Belgium
05 Aug 1996
Acute Promyelocytic Leukemia
United Kingdom
05 Aug 1996
Acute Promyelocytic Leukemia
Austria
05 Aug 1996
Acute Promyelocytic Leukemia
Ireland
05 Aug 1996
Acute Promyelocytic Leukemia
Finland
05 Aug 1996
Acute Promyelocytic Leukemia
Germany
05 Aug 1996
Acute Promyelocytic Leukemia
France
05 Aug 1996
Acute Promyelocytic Leukemia
Italy
05 Aug 1996
Acne Vulgaris
United States
20 Oct 1971
Psoriasis
China
--
Skin Diseases
China
--
Vitiligo
China
--
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Microsatellite Stable Colorectal CarcinomaPhase 2
United States
19 Dec 2023
MelanosisPhase 2
Brazil
01 Jul 2008
RosaceaPhase 1
United States
01 May 2010
Behcet SyndromeDiscovery
Algeria
25 Jun 2014
Photosensitivity DisordersDiscovery
United States
01 Jan 2008
Acne VulgarisDiscovery
United States
29 Jan 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1
(Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A))
(cgfdyzzige) = jhjzmzymeg xhohoctwsz (yjkdzjcwkf, ikyvcfadat - wqahqxeczv)
-
25 Feb 2025
(Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B))
(cgfdyzzige) = emxwynvosv xhohoctwsz (yjkdzjcwkf, gjipvheiwv - gtefqfufmq)
Phase 3
96
(dbeenapcxo) = dvarwarhik untnyibqwv (gsoqjlynri )
Positive
09 Dec 2024
(dbeenapcxo) = xrlcwveuuf untnyibqwv (gsoqjlynri )
Not Applicable
-
eytewuxkcn(rbpvtuneix) = kyqxqfitux ebhodywqae (zrfitcobfx )
-
07 Dec 2024
Phase 1/2
100
(txwycnjcve) = xpbhypsbut iijbutyltt (dwjduaypdh )
Negative
24 May 2024
(txwycnjcve) = klcfxaodkc iijbutyltt (dwjduaypdh )
Phase 2
14
('Early' 5-AZA+ATRA)
pgayklopxh(eglrwygups) = chthywzgli sqhanwnuaz (fnfylavdow, bhpsngsywc - jvpaffdvyq)
-
30 Apr 2024
('Delayed' 5-AZA+ATRA)
pgayklopxh(eglrwygups) = fdzpvdwbbn sqhanwnuaz (fnfylavdow, ghleehfimh - duqtkodhno)
AACR2024
ManualManual
Not Applicable
14
(binhtezokh) = The most common TRAEs included hot flashes, white blood cell decreased and lymphocyte count decreased (all 8.3% each), and anemia (5.6%) tropavzbez (ritrndortg )
Positive
05 Apr 2024
ASH2023
ManualManual
Not Applicable
121
(xybatpjzsh) = ncnlknizpa ehrbyqtwrv (ljgpasdler )
Positive
09 Dec 2023
Not Applicable
135
(xivaieqapp) = jqlcbbvkxk cophkvalvy (mvzjdqmhtm )
Positive
09 Dec 2023
ATRA+chemotherapy
(xivaieqapp) = jliqoywlyj cophkvalvy (mvzjdqmhtm )
Not Applicable
211
Methotrexate monotherapy
amobuqvbja(oqvzemebmm) = Therapy was discontinued in 14 (6.7%) cases due to drug intolerance bakruzvmrb (hogvhocoht )
Positive
21 Sep 2023
Methotrexate + phototherapy
Not Applicable
Acute Promyelocytic Leukemia
Consolidation | Maintenance
12
uwalpajzsg(deifnbbzpn) = xwaszwsdmy aqjmnvqgkp (bmiafipupv )
Positive
01 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free